BU-NOT-SET

CONTACT US
The role of excipient selection in the development of orally disintegrating tablets
  • Drug product
Eyes
Insight
The outlook for a year of change
  • Industry trends
Eyes
Insight
Can oral solid dose keep its place as the leading dosage form?
  • Drug product
Eyes
Insight
Relocating API supply to avoid over-reliance
  • Drug substance
Eyes
Insight
Modified release fixed dose combination product with two poorly soluble drug substances
  • Drug product
pellets
Case study
Patient centricity during drug development and commercialisation
  • Drug product
Eyes
Insight
10 considerations to kick-start your drug development journey
  • Drug product
Eyes
Insight
Guidance for start-ups on drug development
  • Drug product
Eyes
Insight
Drug development for start-ups
  • Drug product
  • Drug substance
Test tubes
White paper
Insight
  • Corporate
Recipharm’s global teams support and engage with their local communities in the fight against COVID-19
Insight
  • Manufacturing
Recipharm launches new virtual inspection and audit tool for customers, in light of COVID-19 outbreak
Brochure
  • Corporate
Recipharm 25 years
Fact sheet
  • Drug substance
API product list
Insight
  • Drug substance
Inhibition of 19S proteasome deubiquitinating activity in Schistosoma mansoni affects viability, oviposition, and structural changes
Insight
  • Industry trends
The demand for antibiotics and its impact on the pharmaceutical industry since the outbreak of COVID-19
Insight
  • Corporate
Women in leadership
Insight
  • Drug product
The state of the oral solid dose development and manufacturing market
Insight
  • Drug substance
Characterising APIs is Essential for Combo Drug Formulations